Abstract:Purpose/Objective(s)Radiation therapy has the widest application to esophageal squamous cell carcinomas (ESCC) patients with locally advanced disease, and plays a central role in the therapeutic strategy. However, the response of this disease to radiation therapy is viable. The human positive cofactor 4 (PC4) plays an important role in various cellular processes including transcription, replication, and Nonhomologous end joining DNA damage repair. The aim of the present study was to investigate the potential roles and underlying molecular mechanisms of PC4 in ESCCs radiosensitivity process and its clinical/prognostic significances.Materials/MethodsWe infected PC4-shRNA lentivirus into ESCC cells to knockdown PC4 expression and examined cell survival in vitro and in vivo, cell apoptosis and mitosis catastrophe (MC) after IR treatment. To investigate the underlying mechanisms, we analyzed the effect of PC4 knockdown on IR-induced XLF foci formation. In addition, the expression dynamics of PC4 was examined by immunohistochemistry (IHC) in a learning cohort (n = 98) and a validation cohort (n = 46) of ESCC patients treat with definite chemoradiation therapy (CRT).ResultsKnockdown of PC4 substantially increased ESCC cells sensitivity to IR in vitro and in vivo and enhanced radiation-induced apoptosis and mitosis catastrophe (MC). Importantly, we demonstrated that depletion of PC4 attenuated not only XLF foci formation but also the recruitment of XLF protein to DSBs. Furthermore, PC4 high expression was evaluated positively to correlate with ESCCs resistance to CRT. Kaplan-Meier curves and multivariate Cox regression analysis showed that PC4 was an independent predictor for short disease-special survival (DSS) of ESCC patients in our both cohorts.ConclusionsOur findings suggested that PC4 protected ESCC cells from IR-induced death through enhancing the NHEJ-promoting functions of XLF, and PC4 could be served as a novel prognostic marker and effective therapeutic target for ESCC. Purpose/Objective(s)Radiation therapy has the widest application to esophageal squamous cell carcinomas (ESCC) patients with locally advanced disease, and plays a central role in the therapeutic strategy. However, the response of this disease to radiation therapy is viable. The human positive cofactor 4 (PC4) plays an important role in various cellular processes including transcription, replication, and Nonhomologous end joining DNA damage repair. The aim of the present study was to investigate the potential roles and underlying molecular mechanisms of PC4 in ESCCs radiosensitivity process and its clinical/prognostic significances. Radiation therapy has the widest application to esophageal squamous cell carcinomas (ESCC) patients with locally advanced disease, and plays a central role in the therapeutic strategy. However, the response of this disease to radiation therapy is viable. The human positive cofactor 4 (PC4) plays an important role in various cellular processes including transcription, replication, and Nonhomologous end joining DNA damage repair. The aim of the present study was to investigate the potential roles and underlying molecular mechanisms of PC4 in ESCCs radiosensitivity process and its clinical/prognostic significances. Materials/MethodsWe infected PC4-shRNA lentivirus into ESCC cells to knockdown PC4 expression and examined cell survival in vitro and in vivo, cell apoptosis and mitosis catastrophe (MC) after IR treatment. To investigate the underlying mechanisms, we analyzed the effect of PC4 knockdown on IR-induced XLF foci formation. In addition, the expression dynamics of PC4 was examined by immunohistochemistry (IHC) in a learning cohort (n = 98) and a validation cohort (n = 46) of ESCC patients treat with definite chemoradiation therapy (CRT). We infected PC4-shRNA lentivirus into ESCC cells to knockdown PC4 expression and examined cell survival in vitro and in vivo, cell apoptosis and mitosis catastrophe (MC) after IR treatment. To investigate the underlying mechanisms, we analyzed the effect of PC4 knockdown on IR-induced XLF foci formation. In addition, the expression dynamics of PC4 was examined by immunohistochemistry (IHC) in a learning cohort (n = 98) and a validation cohort (n = 46) of ESCC patients treat with definite chemoradiation therapy (CRT). ResultsKnockdown of PC4 substantially increased ESCC cells sensitivity to IR in vitro and in vivo and enhanced radiation-induced apoptosis and mitosis catastrophe (MC). Importantly, we demonstrated that depletion of PC4 attenuated not only XLF foci formation but also the recruitment of XLF protein to DSBs. Furthermore, PC4 high expression was evaluated positively to correlate with ESCCs resistance to CRT. Kaplan-Meier curves and multivariate Cox regression analysis showed that PC4 was an independent predictor for short disease-special survival (DSS) of ESCC patients in our both cohorts. Knockdown of PC4 substantially increased ESCC cells sensitivity to IR in vitro and in vivo and enhanced radiation-induced apoptosis and mitosis catastrophe (MC). Importantly, we demonstrated that depletion of PC4 attenuated not only XLF foci formation but also the recruitment of XLF protein to DSBs. Furthermore, PC4 high expression was evaluated positively to correlate with ESCCs resistance to CRT. Kaplan-Meier curves and multivariate Cox regression analysis showed that PC4 was an independent predictor for short disease-special survival (DSS) of ESCC patients in our both cohorts. ConclusionsOur findings suggested that PC4 protected ESCC cells from IR-induced death through enhancing the NHEJ-promoting functions of XLF, and PC4 could be served as a novel prognostic marker and effective therapeutic target for ESCC. Our findings suggested that PC4 protected ESCC cells from IR-induced death through enhancing the NHEJ-promoting functions of XLF, and PC4 could be served as a novel prognostic marker and effective therapeutic target for ESCC.

CHD4 acts as a prognostic factor and drives radioresistance in HPV negative HNSCC

Data from Integrative Analysis Identifies a Novel AXL–PI3 Kinase–PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer

Chd4 is Associated with Poor Prognosis of Non- Small Cell Lung Cancer Patients Through Promoting Tumor Cell Proliferation

Oct4 confers stemness and radioresistance to head and neck squamous cell carcinoma by regulating the homologous recombination factors PSMC3IP and RAD54L

CHD4 Has Oncogenic Functions in Initiating and Maintaining Epigenetic Suppression of Multiple Tumor Suppressor Genes

CHD4 Mediates Proliferation and Migration of Non-Small Cell Lung Cancer Via the RhoA/ROCK Pathway by Regulating PHF5A

Noncanonical HPV carcinogenesis drives radiosensitization of head and neck tumors

CHD4 Promotes Acquired Chemoresistance and Tumor Progression by Activating the MEK/ERK Axis

HPV-mediated regulation of SMAD4 modulates the DNA damage response in head and neck cancer

CHD4 promotes acquired chemoresistance and tumor progression by activating the MEK/ERK axis.

CCR4 is a prognostic biomarker and correlated with immune infiltrates in head and neck squamous cell carcinoma

Therapeutic Targeting of BRD4 in Head Neck Squamous Cell Carcinoma

Proteomic Profiling Identifies PTK2/FAK as a Driver of Radioresistance in HPV-negative Head and Neck Cancer

RNAi screens identify CHD4 as an essential gene in breast cancer growth

A high homologous recombination deficiency score is associated with poor survival and a non-inflamed tumor microenvironment in head and neck squamous cell carcinoma patients

CHMP2A regulates broad immune cell-mediated antitumor activity in an immunocompetent in vivo head and neck squamous cell carcinoma model

Analysis of the role of CHPF in colorectal cancer tumorigenesis and immunotherapy based on bioinformatics and experiments

Comprehensive analysis revealed P4Hs as new biomarkers for prognosis and immunotherapy in head and neck cancer

Abstract LB153: Inhibiting BRD4 as a proposed alternative therapeutic strategy for HPV16-associated head and neck squamous cell carcinoma

The effect of SMAD4 on the prognosis and immune response in hypopharyngeal carcinoma

Human Positive Cofactor 4 (Pc4) Is A Promising Target To Improve The Radiation Therapy Effect Of Esophageal Squamous Cell Carcinomas